| Japanese |
|---|
| Title | 悪性褐色細胞腫の131I-MIBG治療 - SPECTによる吸収線量評価 - |
|---|
| Subtitle | 原著 |
|---|
| Authors | 有竹澄江* |
|---|
| Authors(kana) | |
|---|
| Organization | *東京女子医科大学放射線科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 29 |
|---|
| Number | 6 |
|---|
| Page | 667-678 |
|---|
| Year/Month | 1992/6 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」悪性褐色細胞腫の患者4名に131I-MIBG治療(3.7GBq)を計8回施行し, 治療時の腫瘍吸収線量を測定し, 腫瘍吸収線量と治療効果との関連について検討し, RI治療中の吸収線量測定の臨床的意義について考察した. 131I-MIBG治療時の腫瘍内の放射能をSPECTにより経時的に測定し, SPECTまたはX線CTより腫瘍重量を求め, MIRD法を応用して腫瘍吸収線量を求めた. 腫瘍重量は17-100g(平均40g), 有効半減期は1.3-5.9日(平均3.6日)で, 腫瘍吸収線量は5.4-68Gy(平均40Gy)であった. 腫瘍吸収線量が高いほど, 特に40Gy以上で臨床症状の軽減が顕著であった. また2回および3回の治療を施行した2症例では, 治療回数を重ねるごとに腫瘍吸収線量の低下が認められ, 初回治療の重要性が示唆された. SPECTによる腫瘍吸収線量測定は治療効果判定, 治療方針の決定, さらに現段階におけるRI治療の問題点を知る上で, 臨床的意義があるものと考えられた. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | 131I-MIBG, Pheochromocytoma, Radioisotope therapy, Quantitative SPECT. |
|---|
| English |
|---|
| Title | Radioisotope Therapy of Malignant Pheochromocytoma with Iodine-131 Metaiodobenzylguanidine - Absorbed Dose Assessments Using SPECT - |
|---|
| Subtitle | Original Articles |
|---|
| Authors | Sumie ARITAKE |
|---|
| Authors(kana) | |
|---|
| Organization | Department of Radiology, Tokyo Women's Medical College |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 29 |
|---|
| Number | 6 |
|---|
| Page | 667-678 |
|---|
| Year/Month | 1992/6 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary]The correlation of absorbed doses D (rad) of tumors in 4 patients with malignant pheochromocytoma, who were treated by 131I-MIBG (3.7 GBq), with their clinical courses were analyzed and the clinical significance of determination of absorbed dose was discussed. Absorbed doses of 131I-MIBG in the tumors were measured by using SPECT at the time of therapy. Absorbed dose was calculated based on the MIRD (medical internal radiation dose committee) equation. Tumor volumes were ranged from 17 g-100 g (mean 40 g), effective half lives were ranged from 1.3 days-5.9 days (mean 3.6 days), and tumor absorbed doses were varied between 5.4 Gy-68 Gy (mean 40 Gy). When the absorbed doses of the tumor exceeded over 40 Gy, good clinical responses were obtained. The initial treatment seemed to be important for 131I-MIBG therapy, since the absorbed doses in the following therapy became reduced. These results indicate that the quantitative SPECT for radioisotope therapy is clinically valid and that the calculated absorbed doses correlate well with clinical responses. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | 131I-MIBG, Pheochromocytoma, Radioisotope therapy, Quantitative SPECT. |
|---|